Ian Spendlove

4.2k total citations · 1 hit paper
74 papers, 3.3k citations indexed

About

Ian Spendlove is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Ian Spendlove has authored 74 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Immunology, 37 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in Ian Spendlove's work include Immunotherapy and Immune Responses (29 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Glycosylation and Glycoproteins Research (19 papers). Ian Spendlove is often cited by papers focused on Immunotherapy and Immune Responses (29 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Glycosylation and Glycoproteins Research (19 papers). Ian Spendlove collaborates with scholars based in United Kingdom, United States and Australia. Ian Spendlove's co-authors include Lindy G. Durrant, Ian O. Ellis, Zahra Madjd, Nicholas FS Watson, Judith M. Ramage, J H Scholefield, Linda Morgan, Philip Kaye, A Austin and Stephen Ryder and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Ian Spendlove

72 papers receiving 3.2k citations

Hit Papers

Randomized, Placebo-Controlled Trial of Pioglitazone in N... 2008 2026 2014 2020 2008 100 200 300 400 500

Peers

Ian Spendlove
Jinzhao Hou United States
Louis Fabri Australia
Sajjad A. Qureshi United States
Martin Hegen United States
Julie A. Ellerhorst United States
Hans Morreau Netherlands
Andrea van Elsas Netherlands
Jinzhao Hou United States
Ian Spendlove
Citations per year, relative to Ian Spendlove Ian Spendlove (= 1×) peers Jinzhao Hou

Countries citing papers authored by Ian Spendlove

Since Specialization
Citations

This map shows the geographic impact of Ian Spendlove's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Spendlove with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Spendlove more than expected).

Fields of papers citing papers by Ian Spendlove

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Spendlove. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Spendlove. The network helps show where Ian Spendlove may publish in the future.

Co-authorship network of co-authors of Ian Spendlove

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Spendlove. A scholar is included among the top collaborators of Ian Spendlove based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Spendlove. Ian Spendlove is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fadhil, Wakkas, Nigel P. Mongan, Arvydas Laurinavičius, et al.. (2023). Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided “immune-hot” colorectal cancers. Frontiers in Immunology. 14. 1057292–1057292. 12 indexed citations
2.
Vankemmelbeke, Mireille, Richard S. McIntosh, Ian Daniels, et al.. (2020). Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan–Targeting Antibodies without the Need for Immune Effector Cells or Complement. Cancer Research. 80(16). 3399–3412. 7 indexed citations
3.
Aram, Jehan, Nanci Frakich, Elena Morandi, et al.. (2020). Increased IL-2 and Reduced TGF-β Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis. Biomedicines. 8(7). 226–226. 7 indexed citations
4.
Nwosu, L.N., David R. Wilson, R. Hill, et al.. (2018). Molecular expression patterns in the synovium and their association with advanced symptomatic knee osteoarthritis. Osteoarthritis and Cartilage. 27(4). 667–675. 25 indexed citations
5.
Johnson, Michael, Dominick Shaw, Ian Spendlove, et al.. (2016). A prebiotic galactooligosaccharide mixture reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway inflammation. British Journal Of Nutrition. 116(5). 798–804. 32 indexed citations
6.
Vankemmelbeke, Mireille, Richard S. McIntosh, Philip A. Clarke, et al.. (2015). Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity. Clinical Cancer Research. 21(13). 2963–2974. 19 indexed citations
7.
Khoo, Eric Yin-Hao, M C Stevenson, Richard Cross, et al.. (2012). Elevation of Alanine Transaminase and Markers of Liver Fibrosis After a Mixed Meal Challenge in Individuals with Type 2 Diabetes. Digestive Diseases and Sciences. 57(11). 3017–3025. 8 indexed citations
8.
Durrant, Lindy G., et al.. (2011). Using monoclonal antibodies to stimulate antitumor cellular immunity. Expert Review of Vaccines. 10(7). 1093–1106. 11 indexed citations
9.
Metheringham, Rachael L., et al.. (2009). DNA vaccination with T‐cell epitopes encoded within Ab molecules induces high‐avidity anti‐tumor CD8+ T cells. European Journal of Immunology. 40(3). 899–910. 20 indexed citations
10.
Duncan, Timothy J., Ahmad Al‐Attar, Phil Rolland, et al.. (2008). Vascular Endothelial Growth Factor Expression in Ovarian Cancer: A Model for Targeted Use of Novel Therapies?. Clinical Cancer Research. 14(10). 3030–3035. 96 indexed citations
11.
Aithal, Guruprasad P., James A. Thomas, Philip Kaye, et al.. (2008). Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis. Gastroenterology. 135(4). 1176–1184. 545 indexed citations breakdown →
12.
Ullenhag, Gustav, et al.. (2008). T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clinical Immunology. 128(2). 148–154. 21 indexed citations
13.
Abbott, Rachel J.M., Ian Spendlove, Pietro Roversi, et al.. (2007). Structural and Functional Characterization of a Novel T Cell Receptor Co-regulatory Protein Complex, CD97-CD55. Journal of Biological Chemistry. 282(30). 22023–22032. 54 indexed citations
14.
Ramage, Judith M., et al.. (2006). The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2. Cancer Immunology Immunotherapy. 55(8). 1004–1010. 1 indexed citations
15.
Madjd, Zahra, et al.. (2005). Prognostic significance of SC101, a monoclonal Antibody against Lewisy/b in breast tumors. Cancer Research. 65. 360–361.
16.
Madjd, Zahra, Ian Spendlove, Ian O. Ellis, S Pinder, & LG Durrant. (2005). Total Loss of MHC Class I is an Independent Indicator of Good Prognosis in Breast Cancer. SHILAP Revista de lepidopterología. 34. 51–52. 5 indexed citations
17.
Watson, Nicholas FS, Lindy G. Durrant, Zahra Madjd, et al.. (2005). Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. Cancer Immunology Immunotherapy. 55(8). 973–980. 59 indexed citations
18.
Watson, Nicholas FS, Zahra Madjd, Ian Spendlove, et al.. (2005). Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients. World Journal of Surgical Oncology. 3(1). 47–47. 39 indexed citations
19.
Durrant, LG & Ian Spendlove. (2003). Cancer vaccines entering Phase III clinical trials. Expert Opinion on Emerging Drugs. 8(2). 489–500. 17 indexed citations
20.
Lowe, James, Graham Lennox, Ian Pike, et al.. (1992). Ballooned neurons in several neurodegenerative diseases and stroke contain αB crystallin. Neuropathology and Applied Neurobiology. 18(4). 341–350. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026